Menu
Search
|

Menu

Close
X

Audentes Therapeutics Inc BOLD.OQ (NASDAQ Stock Exchange Global Market)

37.90 USD
-0.18 (-0.47%)
As of Jul 19
Previous Close 38.08
Open 38.16
Volume 110,051
3m Avg Volume 154,740
Today’s High 38.49
Today’s Low 37.52
52 Week High 42.48
52 Week Low 18.00
Shares Outstanding (mil) 44.29
Market Capitalization (mil) 1,678.61
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.15 Mean rating from 13 analysts

KEY STATS

Revenue (mm, USD)
FY19
0
FY18
0
FY17
0
FY16
0
EPS (USD)
FY19
-1.132
FY18
-3.398
FY17
-2.743
FY16
-3.009
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
34.52
Price to Sales (TTM)
vs sector
--
7.97
Price to Book (MRQ)
vs sector
4.13
4.45
Price to Cash Flow (TTM)
vs sector
--
24.33
Total Debt to Equity (MRQ)
vs sector
0.00
17.60
LT Debt to Equity (MRQ)
vs sector
0.00
12.58
Return on Investment (TTM)
vs sector
-38.84
12.69
Return on Equity (TTM)
vs sector
-40.46
17.17

EXECUTIVE LEADERSHIP

Matthew Patterson
Chairman of the Board, Chief Executive Officer, Since 2018
Salary: $542,000.00
Bonus: --
Natalie Holles
President, Chief Operating Officer, Since 2018
Salary: $448,211.00
Bonus: --
Thomas Schuetz
Co-Founder, Independent Director, Since 2013
Salary: --
Bonus: --
Thomas Soloway
Chief Financial Officer, Executive Vice President, Since 2019
Salary: $397,950.00
Bonus: --
Mark Meltz
Senior Vice President, General Counsel, Since 2019
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

600 California St Fl 17
SAN FRANCISCO   CA   94108-2725

Phone: +1415.6386556

Audentes Therapeutics, Inc. is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT). The Company's subsidiary is Audentes Therapeutics UK Ltd. As of September 30, 2016, the Company had not generated any revenues.

SPONSORED STORIES